Credit Suisse Group AG restated their neutral rating on shares of Charles River Laboratories International Inc. (NYSE:CRL) in a research note published on Friday.

Several other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Charles River Laboratories International from a buy rating to a hold rating in a research note on Friday, July 22nd. Citigroup Inc. upped their target price on shares of Charles River Laboratories International from $85.00 to $90.00 and gave the company a neutral rating in a research report on Thursday, August 4th. Evercore ISI restated a hold rating and set a $91.50 target price (up from $83.50) on shares of Charles River Laboratories International in a research report on Thursday, August 4th. Finally, Jefferies Group upped their target price on shares of Charles River Laboratories International from $94.00 to $100.00 and gave the company a buy rating in a research report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. Charles River Laboratories International presently has a consensus rating of Hold and a consensus target price of $86.21.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Shares of Charles River Laboratories International (NYSE:CRL) opened at 83.34 on Friday. The firm has a 50-day moving average of $82.37 and a 200 day moving average of $82.30. Charles River Laboratories International has a one year low of $59.99 and a one year high of $89.18. The stock has a market capitalization of $3.94 billion, a price-to-earnings ratio of 28.16 and a beta of 1.13.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.10 by $0.10. The business had revenue of $434.10 million for the quarter, compared to analysts’ expectations of $425.05 million. Charles River Laboratories International had a net margin of 9.49% and a return on equity of 25.18%. The business’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.96 EPS. On average, equities research analysts predict that Charles River Laboratories International will post $4.46 EPS for the current year.

In related news, insider Davide Molho sold 7,877 shares of the stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $84.10, for a total transaction of $662,455.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard F. Wallman sold 7,740 shares of the stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $88.00, for a total transaction of $681,120.00. Following the sale, the director now directly owns 24,190 shares of the company’s stock, valued at approximately $2,128,720. The disclosure for this sale can be found here. Corporate insiders own 2.30% of the company’s stock.

A number of large investors have recently bought and sold shares of CRL. Norges Bank purchased a new stake in Charles River Laboratories International during the fourth quarter worth approximately $49,698,000. Glenmede Trust Co. NA boosted its stake in Charles River Laboratories International by 0.4% in the first quarter. Glenmede Trust Co. NA now owns 45,799 shares of the company’s stock worth $3,477,000 after buying an additional 160 shares during the last quarter. Aperio Group LLC boosted its stake in Charles River Laboratories International by 15.8% in the first quarter. Aperio Group LLC now owns 18,133 shares of the company’s stock worth $1,377,000 after buying an additional 2,470 shares during the last quarter. Nisa Investment Advisors L.L.C. boosted its stake in Charles River Laboratories International by 5.7% in the first quarter. Nisa Investment Advisors L.L.C. now owns 9,300 shares of the company’s stock worth $706,000 after buying an additional 500 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its stake in Charles River Laboratories International by 19.5% in the first quarter. TIAA CREF Investment Management LLC now owns 312,921 shares of the company’s stock worth $23,763,000 after buying an additional 51,097 shares during the last quarter. 96.19% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.